LATEST

Novel drug reduces monthly migraine daysA global phase 3 study of erenumab (Amgen and Novartis) showed that the drug was able to prevent migraines headaches.
Breakthrough lymphoma drug on the horizonFDA granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris, Seattle Genetics) to treat patients with the most common subtypes of lymphoma.
Gilead promises generic versions of new hepatitis drugAfter Gilead received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. That is good news for Gilead, which has been targeted by Congressional representatives for the high cost of Sovaldi and Harvoni hepatitis C treatments.
Insulin makers accused of price collusionU.S. congressmen last week asked the Department of Justice and the Federal Trade Commission to investigate three insulin makers for price collusion—the latest in concerns over insulin prices.
Statin prescribing varies in patients with diabetesWide variation exists in practice-level statin prescribing for patients with diabetes, according to a new study.
Insurer diabetes program engages consumers, lowers costs
Insurer diabetes program engages consumers, lowers costsAnthem Blue Cross recently launched a year-long diabetes prevention program to educate, treat and support its qualified California members who are at risk of developing type 2 diabetes.
Clear skin within reach for psoriasis patientsNew data presented at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, this week shows that secukinumab (Cosentyx, Novartis) has long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis.
Lung cancer drug approvedSoon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC).
New antibiotic for MRSA on the horizon
New antibiotic for MRSA on the horizonAs the healthcare profession continues to face challenges with antibiotic resistance, drugmakers are developing novel antibiotics that will be effective against some of the worst infections. One drugmaker submitted New Drug Applications (NDAs) for approval of IV and oral delafloxacin (Baxdela) to FDA.
Sharp price increases for cancer drugs
Sharp price increases for cancer drugsA majority of oncology drugs—particularly older cancer drugs—had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street.

Poll

View Results